Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.

Item

http://www.wikidata.org/entity/Q34594956

Q34594956

about

Perioperative and Palliative Chemotherapy for Esophageal Cancer Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.DCF intraperitoneal and intravenous dual chemotherapy regimen for advanced gastric cancer: A feasibility study The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.Treatment options in patients with metastatic gastric cancer: current status and future perspectives Association of angiogenic factors with prognosis in esophageal cancer.Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts.Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction foll A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer.Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers.Effect of epidermal growth factor receptor status on the outcomes of patients with metastatic gastric cancer: A pilot study.Optimal chemotherapy for advanced gastric cancer: is there a global consensus?Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer.Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany.Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis.Esophageal Cancer: New Insights into a Heterogenous Disease.Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor.Prognostic impact of phosphorylated mitogen-activated protein kinase expression in patients with metastatic gastric cancer.Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.Weekly Taxotere and cisplatin with continuous-infusion 5-fluoruracil for the treatment of advanced gastric and esophageal cancer: a prospective, observational, single-institution experience.Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer - the multinational MATEO study.Outcome of operative therapy of hepatic metastatic stomach carcinoma: a retrospective analysis.Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study.Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort.Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer.CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach.A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval.Metastatic adenocarcinomas of the stomach or esophagogastric junction (UICC stage IV) are not always a palliative situation: a retrospective analysis.Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation.

P2860

Q26753865-78B7CD49-F67B-4A5F-9B37-6127CC609377 Q28079750-3D51E64B-CF93-44E5-B884-2236EA1F55BF Q33405235-6DD2AC53-3D81-4589-97E1-B9E47A377A97 Q33418948-78CE5E4B-D283-4084-AEFA-3B905641E571 Q34478504-AC407D02-A0F6-489C-8349-C76934419924 Q34658209-51E439C3-18EC-41E0-A744-7B4672AA9ED9 Q34661367-2FBF80A3-DB16-4F45-B9F6-193DFB8E5CCA Q35185524-EBE379F7-1460-4CD7-B647-7CC8DE46F611 Q35208094-F551AF5C-AB5E-4AE8-901B-A91892155F1D Q36214394-07934401-A03B-44AE-B7E1-99F21FEBF495 Q36516605-20A4A7F0-DA79-4E1B-A85D-712FE725A580 Q36594055-AFA9C46D-2E91-406E-A90D-F7B7F639030F Q36671857-FFB35666-F461-4B09-8444-175235277DDD Q37077239-8DC3CFD1-5BFB-47E3-A95B-CC7AAE9398A6 Q37388719-7CC8831B-2778-478E-828A-2DAB6BB443B1 Q38139297-11C272CB-1A9B-43B4-A832-8860CA79BD28 Q38222270-195E184E-CDE3-4B0D-BB94-C742C7F75ACF Q38363108-5F8A73BD-A0E6-4AF8-B0F1-CA3E8409BB6F Q38377462-869BCF2C-7488-44F7-B437-2673FA692195 Q38420500-A78AFA43-7A81-4E13-88C1-C7B1B9EF2B39 Q38663129-321F9BC6-C9B6-4AA2-879B-CC0EC040815C Q38734003-8698EEC0-4756-4361-B6EE-B62CEF0C4535 Q39231206-C604E5D6-B270-415F-AD38-72A6F66DEEBD Q39497734-7B270F83-8344-42CB-8A53-65E47E6F578F Q39523783-7ABF2E9F-1F53-4D7A-B6CE-DB373D4D0172 Q40282337-98F6F382-C16D-44FB-AFBD-07B394B9AE60 Q40315009-0CCFC2BE-7CAB-438F-8159-5F3C862E473F Q41187621-2ADD06D0-57E5-447A-AAB3-F08E62BF71A9 Q41195879-8EA09285-C2CF-4C58-90A4-46A96801ACDB Q43976543-8493D912-28D6-4BD3-9CBC-A81A68038B45 Q43978326-2F1BA5C0-289D-4787-903A-4425F08CE975 Q44136997-EC1CF355-BC69-48E3-A3FD-B3B2862592F2 Q44143001-5D46B2EF-D9A7-4926-B9ED-3F88813DAEE7 Q45155024-1B5EF1A1-CFC8-4F4B-A0E1-906EC3BFD256 Q49337286-A7BBE142-C238-4E8B-852C-034A2432448F Q49504289-04E6D955-B5CF-4794-86F2-50E517A5FCF0 Q49645479-27843A4E-5049-413B-B81B-73F731059F11 Q50119733-9C061B45-BCD4-4050-9C9F-B4AE9732F6A7 Q50761729-D71BC145-379D-42DE-A199-5B7DD3357C20 Q53070391-4C3CE42A-3AE3-46F8-AD58-E5196D47DAC1

P2860

Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.

Item

http://www.wikidata.org/entity/Q34594956

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu